Dainippon Sumitomo ups profit outlook, launches lurasidone in US
This article was originally published in Scrip
Executive Summary
Lower than forecast selling, general and administrative and R&D costs have led Dainippon Sumitomo Pharma (DSP) to raise its net profit guidance for the fiscal year ending 31 March by ¥2.0 billion to ¥11.0 billion ($134.8 million).